More recently Scheepstra et al. highlighted the potential to optimise proteolysis-targeting chimera (PROTAC) mediated protein degradation has displayed anti-tumour effects against epigenetic regulators, e.g., TRIM24 suggesting potential application to EZH2 methyltransferase activity, which requires further work into understanding the mechanism of action for EZH2 [94]. Here, EZH2 is linked to neoplasm.